Biotech's Payoff Isn't All In Bucks

In response to the cover language "Biotech: Why it's not paying off" (Science & Technology, Sept. 26), I have one question: Paid off for whom? The industry has certainly paid off for the millions of people suffering from diseases who, thanks to biotechnology, are alive and doing well. It has paid off in terms of the creation of many jobs for Americans and has given the U.S. a worldwide leadership position in a high-technology field.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.